The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Zanubrutinib in R/R B-cell malignancies intolerant to other BTK inhibitors
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the ongoing Phase II, multicenter study (NCT04116437) aiming to evaluate the efficacy and safety of zanubrutinib monotherapy in patients with relapsed/refractory (R/R) B-cell malignancies, who have become intolerant to previous BTK inhibitors (BTKi). In a group of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) treated with zanubrutinib, the majority reported no BTKi-related adverse events (AEs). The few AEs that occurred were mild and none led to dose modification or treatment discontinuation. In patients evaluable for efficacy, all achieved at least stable disease. These findings show that zanubrutinib is effective and has a tolerable safety profile in CLL and SLL patients, suggesting that it may provide a potential option after intolerance to other BTKi. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
